Organization and Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Revenue by Geographic Areas and Segment

The following tables summarize the revenue by segment and region for the periods presented (in thousands):

	Year Ended December 31, 2021
	Nucleic Acid Production		Biologics Safety Testing		Protein Detection		Total
North America	$	280,369	$	25,686	$	11,016	$	317,071
Europe, the Middle East and Africa	377,325		15,597		4,752		397,674
Asia Pacific	54,114		26,471		3,068		83,653
Latin and Central America	56		663		123		842
Total revenue	$	711,864	$	68,417	$	18,959	$	799,240

	Year Ended December 31, 2020
	Nucleic Acid Production		Biologics Safety Testing		Protein Detection		Total
North America	$	115,216	$	21,787	$	13,343	$	150,346
Europe, the Middle East and Africa	69,637		14,862		5,606		90,105
Asia Pacific	21,444		17,946		3,783		43,173
Latin and Central America	23		302		149		474
Total revenue	$	206,320	$	54,897	$	22,881	$	284,098

	Year Ended December 31, 2019
	Nucleic Acid Production		Biologics Safety Testing		Protein Detection		Total
North America	$	49,757	$	18,984	$	15,284	$	84,025
Europe, the Middle East and Africa	15,975		12,102		6,805		34,882
Asia Pacific	6,843		12,964		3,784		23,591
Latin and Central America	27		366		249		642
Total revenue	$	72,602	$	44,416	$	26,122	$	143,140

Summary of Property and Equipment

Depreciation is computed using the straight-line method over the following estimated useful lives:

Assets	Useful Lives
Leasehold improvements	5 - 15 years
Furniture, fixtures, equipment and software	3 - 11 years

Property and equipment consisted of the following as of the periods presented (in thousands):

	December 31, 2021		December 31, 2020
Land	$	—	$	818
Buildings	—		2,129
Buildings capitalized under lease finance obligations	—		61,202
Leasehold improvements	18,162		1,637
Furniture, fixtures, and equipment	31,065		23,157
Software	2,713		2,632
Total	51,940		91,575
Less accumulated depreciation	(12,532)		(10,647)
Total	39,408		80,928
Construction in-progress	6,924		20,377
Total property and equipment, net	$	46,332	$	101,305

Summary of Concentration of Revenue

The following table summarizes revenue from each of our customers who individually accounted for 10% or more of our total revenue or accounts receivable for the periods presented:

	Revenue						Accounts Receivable, net
	Years Ended December 31,						As of December 31,
	2021		2020		2019		2021		2020
BioNTech SE	29.5	%	16.7	%	*		*		*
Pfizer Inc.	23.3	%	14.2	%	*		23.6	%	45.1	%
CureVac N.V.	15.3	%	*		*		46.5	%	12.8	%
Thermo Fisher Scientific Inc.	*		*		10.4	%	*		*
Nacalai USA, Inc.	*		*		*		11.6	%	*

____________________

*Less than 10%

Summary of Impact of Accounting Principle Adoption

The impact of the adoption of Topic 842 on the balance sheet as of January 1, 2021 was as follows (in thousands):

	Balance as of December 31, 2020		Adjustments due to Adoption of Topic 842		Balance as of January 1, 2021
Assets:
Prepaid expenses and other current assets	$	11,095	$	(1,987)	$	9,108
Property and equipment, net	101,305		(59,759)		41,546
Deferred tax assets	431,699		(424)		431,275
Other assets	4,158		57,227		61,385
Liabilities:
Accrued expenses and other current liabilities	38,546		2,570		41,116
Lease facility financing obligation, less current portion	56,167		(56,167)		—
Other long-term liabilities	2,231		44,200		46,431
Stockholders' equity:
Retained earnings	854		1,670		2,524
Non-controlling interest	66,235		2,784		69,019